Biomea Fusion, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-04-30: Study NCT07502508; Company role Lead sponsor; Phase Phase 2; Status Recruiting.
- 2026-03-27: Study NCT07502495; Company role Lead sponsor; Phase Phase 2; Status Active not recruiting.
- 2025-10-23: Study NCT07223216; Company role Lead sponsor; Phase Phase 1; Status Active not recruiting.
- 2025-09-11: Study NCT07254286; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-04-30 | NCT07502508 Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy | Lead sponsor | Phase 2 | Recruiting | Type 2 Diabetes | 60 | 2027-07 |
| 2026-03-27 | NCT07502495 Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets | Lead sponsor | Phase 2 | Active not recruiting | Type 2 Diabetes | 64 | 2027-09 |
| 2025-10-23 | NCT07223216 Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants | Lead sponsor | Phase 1 | Active not recruiting | Obesity | 80 | 2026-06 |
| 2025-09-11 | NCT07254286 Food Effect Study in Healthy Volunteers | Lead sponsor | Phase 1 | Completed | Healthy Volunteer | 60 | 2026-01-14 |
| 2023-12-28 | NCT06152042 Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus | Lead sponsor | Phase 2 | Completed | Type 1 Diabetes Mellitus | 37 | 2025-07-18 |
| 2023-07-26 | NCT05918692 A Phase 1 Study of BMF-500 in Adults With Acute Leukemia | Lead sponsor | Phase 1 | Completed | Acute Myeloid Leukemia | 35 | 2026-04-30 |
| 2023-01-12 | NCT05631574 Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer | Lead sponsor | Phase 1 | Terminated | Non Small Cell Lung Cancer; Pancreatic Cancer; Colorectal Cancer; NSCLC; PDAC; CRC; Relapsed Cancer; Refractory Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer; Stage III Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer; Stage III Colorectal Cancer; Stage IV Colorectal Cancer; Stage III NSCLC; Stage IV NSCLC; KRAS Mutation-Related Tumors | 13 | 2025-01-15 |
| 2022-08-17 | NCT05731544 Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D) | Lead sponsor | Phase 1, Phase 2 | Completed | Type 2 Diabetes Mellitus | 443 | 2025-07-08 |
| 2022-01-24 | NCT05153330 Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL | Lead sponsor | Phase 1 | Terminated | Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Acute Mixed-Phenotype Leukemia; Cancer; Refractory; Progression; Diffuse Large B Cell Lymphoma; Multiple Myeloma; Lymphoma; Lymphoma, Non-Hodgkin; Myeloma, Plasma-Cell; Myelomatosis; Plasma Cell Myeloma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | 55 | 2025-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |